Evicenter
Stelara (ustekinumab) in Plaque psoriasis
Manufacturer
Janssen Biotech, Inc.
Prescribing information
Stelara (opens in a new tab)
Questions
29
Last updated

All questions

Clinical trials: Stelara (ustekinumab) in plaque psoriasis

7 questions · 2 sources

Clinical trials

How were the Stelara adult plaque psoriasis trials designed?

Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Who was enrolled in the Stelara adult plaque psoriasis trials?

Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Study results

How effective is Stelara for plaque psoriasis at 12 weeks (PHOENIX 1 and 2)?

Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Note: The prescribing information reports the adult trials as Ps STUDY 1 and Ps STUDY 2; its Week 12 counts match those the HCP site gives for PHOENIX 1 and PHOENIX 2. Table 12 columns are placebo, STELARA 45 mg, and STELARA 90 mg for each trial.

How many patients reached PASI 90 on Stelara at Week 12 (PHOENIX 2)?

Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Subgroup results

Does Stelara work as well in patients over 100 kg?

Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Note: Table 13 columns are placebo, STELARA 45 mg, and STELARA 90 mg for each trial.

Maintenance of response

What happens when Stelara is stopped after a response in plaque psoriasis?

Applies to Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Pediatric efficacy

How effective is Stelara for plaque psoriasis in children 12 and older?

Applies to Pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy